Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Sana Biotechnology Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.75 (market cap $2.98B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is far larger — about 3.6× Sana Biotechnology Inc's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Sana Biotechnology Inc for 23 Days on average.
| FNGU | SANA | |
|---|---|---|
Market Cap | $2.98B | $836.71M |
Volume | 4,682,352 | 4,507,444 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $5.92 |
52-Week Low | $13.73 | $2.68 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.82, down 1.02% today. Technical signals are bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Support and resistance levels are tightly clustered between $33 and $39, indicating a critical price zone. Recent news highlights the ETN's high volatility, having lost 87% during past tech sector downturns, underscoring its leveraged risk profile.
The outlook for FNGU hinges on sustained strength in its underlying tech holdings like Nvidia and Apple. While bullish momentum offers upside potential, the extreme leverage amplifies risks during market corrections. Investors face significant volatility, with losses magnified in downturns, making it suitable only for those with high risk tolerance and short-term horizons.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
